Compare · AVTR vs ILMNV
AVTR vs ILMNV
Side-by-side comparison of Avantor Inc. (AVTR) and Illumina Inc. (ILMNV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and ILMNV operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR carries a market cap of $5.34B.
- AVTR has hit the wire 5 times in the past 4 weeks while ILMNV has been quiet.
- AVTR has more recent analyst coverage (25 ratings vs 0 for ILMNV).
- Company
- Avantor Inc.
- Illumina Inc.
- Price
- $7.91+2.00%
- -
- Market cap
- $5.34B
- -
- 1M return
- +2.93%
- -
- 1Y return
- -36.67%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 0
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Latest AVTR
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Avantor® Announces Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer
- Avantor® Unifies Masterflex® Portfolio to Streamline Fluid Management from R&D to Bioprocess Manufacturing
- Avantor® Enhances U.S. Biomanufacturing Infrastructure with Expanded Stability and Microbial Testing Facility
- SEC Form 4 filed by Eck Steven W
- Avantor® to Report First Quarter 2026 Earnings on Wednesday, April 29, 2026
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Avantor® Announces CFO Transition
- SEC Form DEFA14A filed by Avantor Inc.
- SEC Form DEF 14A filed by Avantor Inc.
Latest ILMNV
- SVP, Chief Commercial Officer Cunningham Everett was granted 36,860 shares (SEC Form 4)
- Director Ullem Scott B. was granted 205 shares, increasing direct ownership by 5% to 4,550 units (SEC Form 4)
- Amendment: Illumina Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities
- Amendment: Illumina Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits